Roberto Iacone

Roberto Iacone is the Chief Executive Officer at Alentis Therapeutics since July 2020. Prior to this, Roberto served as Entrepreneur In Residence at Versant Ventures from March 2017 to March 2020 and VP Biology and Translational Medicine at Ridgeline Therapeutics from April 2017 to February 2020. With a background in stem cell research and rare genetic diseases, Roberto has also held positions at Black Diamond Therapeutics, Bright Peak Therapeutics, and Roche. Roberto's expertise includes implementing patient-specific iPSCs for identifying therapeutic approaches, drug discovery programs for rare diseases like AMD, and stem cell research for diabetic cardiovascular indications. Roberto holds an MD/PHD from Max Planck Institute/University of Naples Federico II.